www.fdanews.com/articles/81408-epix-gets-eu-approval-for-blood-pool-contrast-agent
EPIX GETS EU APPROVAL FOR BLOOD POOL CONTRAST AGENT
October 5, 2005
Epix Pharmaceuticals Inc. (EPIX.O: Quote, Profile, Research) on Wednesday said it won European regulatory approval for its blood pool contrast agent Vasovist. EPIX, a developer of pharmaceuticals for magnetic resonance imaging (MRI), said Vasovist is approved for visualization of abdominal or limb vessels in patients with known or suspected vascular disease using magnetic resonance angiography.